Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Thrombocytopenia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemoglobinuria, Paroxysmal 1Congenital Abnormalities 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory 1AIDS-related Diffuse Large Cell Lymphoma 1

Interventions

Cytarabine 30fludarabine phosphate 13Etoposide 12Cyclophosphamide 11Mitoxantrone 10Peripheral Blood Stem Cell Transplantation 9Decitabine 9Tacrolimus 7Filgrastim 7Mycophenolic Acid 6Bortezomib 6Idarubicin 5Flow Cytometry 5Daunorubicin 5Antilymphocyte Serum 5tipifarnib 4sargramostim 4Whole-Body Irradiation 4Vorinostat 4Radiotherapy 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Clofarabine 4Busulfan 4alvocidib 3Polymerase Chain Reaction 3Melphalan 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tanespimycin 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Congenital Abnormalities × Bryostatins × Clear all
NCT00012376 2013-01-09

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

National Cancer Institute (NCI)

Phase 1 Completed
35 enrolled
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Blast Crisis, Hemoglobinuria, Paroxysmal, Thrombocytopenia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡